STORM Therapeutics announces closing of USD $30M Series B financing
- Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias
- Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification
14 December 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced the successful completion of a USD $30 million Series B financing round.
